{"id":"ebr-gzr","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Elbasvir is an NS5A inhibitor that disrupts hepatitis C virus replication and assembly, while grazoprevir is an NS3/4A protease inhibitor that prevents viral polyprotein processing. Together, they provide direct-acting antiviral activity against hepatitis C virus across multiple genotypes with a high barrier to resistance.","oneSentence":"EBR/GZR is a fixed-dose combination of elbasvir and grazoprevir that inhibits hepatitis C virus NS5A and NS3/4A proteases to block viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:11.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotypes 1, 4, 5, 6)"}]},"trialDetails":[{"nctId":"NCT02613403","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-10","conditions":"Hepatitis, Hepatitis C, Digestive System Diseases","enrollment":94},{"nctId":"NCT03379506","phase":"PHASE2","title":"Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-01-25","conditions":"HCV Infection","enrollment":57},{"nctId":"NCT03496233","phase":"PHASE3","title":"Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo","startDate":"2018-09-19","conditions":"Chronic HCV Hepatitis","enrollment":75},{"nctId":"NCT02786537","phase":"PHASE4","title":"Study of Oral Treatments for Hepatitis C","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":1275},{"nctId":"NCT02105662","phase":"PHASE3","title":"An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-06-03","conditions":"Chronic Hepatitis C","enrollment":218},{"nctId":"NCT03111108","phase":"PHASE4","title":"Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-06-20","conditions":"Hepatitis C Virus (HCV) Infection","enrollment":117},{"nctId":"NCT03420300","phase":"PHASE4","title":"EBR/GZR for HCV-1b Patients Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-06-05","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT03221582","phase":"PHASE4","title":"Impact of Hepatitis C Therapy and Bone Health","status":"TERMINATED","sponsor":"Dallas VA Medical Center","startDate":"2017-08-28","conditions":"Human Immunodeficiency Virus, Hepatitis C","enrollment":6},{"nctId":"NCT02601573","phase":"PHASE2","title":"Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-05","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT02332707","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-01-22","conditions":"Hepatitis C","enrollment":443},{"nctId":"NCT02115321","phase":"PHASE2, PHASE3","title":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-09","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT02897596","phase":"PHASE3","title":"Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2017-04-28","conditions":"Hepatitis C, HIV","enrollment":62},{"nctId":"NCT02105454","phase":"PHASE2","title":"Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-23","conditions":"Hepatitis C Virus","enrollment":79},{"nctId":"NCT03585101","phase":"PHASE4","title":"A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2018-08","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03143998","phase":"PHASE4","title":"Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-12","conditions":"Hepatitis C","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":72,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zepatier"],"phase":"marketed","status":"active","brandName":"EBR/GZR","genericName":"EBR/GZR","companyName":"Dallas VA Medical Center","companyId":"dallas-va-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EBR/GZR is a fixed-dose combination of elbasvir and grazoprevir that inhibits hepatitis C virus NS5A and NS3/4A proteases to block viral replication. Used for Chronic hepatitis C virus infection (genotypes 1, 4, 5, 6).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}